Skip to main
BWAY

Brainsway (BWAY) Stock Forecast & Price Target

Brainsway (BWAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BrainsWay Ltd. has demonstrated substantial growth potential, as evidenced by a 43% year-over-year increase in remaining performance obligations, totaling approximately $70 million. The company’s shipment of 95 Deep TMS systems in the fourth quarter reflects a notable 27% rise, bolstering its revenue projections with a forecasted increase from $65.6 million to $66.8 million for full-year 2026 and a new estimate of $81.2 million for 2027. Additionally, the approval of Neurolief's ProlivRx device enhances BrainsWay's strategic position and supports a favorable medium- to long-term financial outlook, further solidifying the stock's growth narrative.

Bears say

BrainsWay Ltd faces significant challenges that contribute to a negative outlook on its stock performance. Key risks include a slower than projected uptake of its Deep TMS systems, difficulties in expanding reimbursement and market access, and the potential inability to advance its treatment for additional indications. Additionally, there exists a concern regarding long-term dilution risk, which could further impact shareholder value and overall financial stability.

Brainsway (BWAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Brainsway (BWAY) Forecast

Analysts have given Brainsway (BWAY) a Buy based on their latest research and market trends.

According to 2 analysts, Brainsway (BWAY) has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Brainsway (BWAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.